Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.66 |
| ▸ | MMP13 | P45452 | 9/20 | 0.66 |
| ▸ | MMP3 | P08254 | 8/20 | 0.66 |
| ▸ | MMP9 | P14780 | 8/20 | 0.66 |
| ▸ | MMP1 | P03956 | 7/20 | 0.66 |
| ▸ | MMP7 | P09237 | 7/20 | 0.66 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.62 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084071 | 0.88 | ADAMTS4 (0.65) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL3100292 | 0.82 | MMP2 (0.66) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL3094363 | 0.81 | CSGALNACT1 (0.58) | — | |
| SCHEMBL3097150 | 0.81 | CSGALNACT1 (0.58) | — | |
| SCHEMBL4828284 | 0.81 | GAA (0.67) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL4834723 | 0.81 | GAA (0.67) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL7408882 | 0.81 | MMP2 (1.00) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL7408889 | 0.81 | MMP2 (1.00) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL3091604 | 0.80 | MMP2 (0.77) | MMP2MMP13MMP3MMP9MMP1 | |
| SCHEMBL20124752 | 0.78 | ADAMTS4 (1.00) | MMP2MMP13MMP3MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | MMP2 2401/4885MMP13 2261/4885MMP3 2390/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | MMP2 2401/4885MMP13 2261/4885MMP3 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.